Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective

References

• de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat. 2011;22:102–105. doi:10.3109/0954663100363681720687846
   PubMed Web of Science ®Google Scholar
• Brunasso AMG, Massone C. Psoriasis and palmoplantar pustulosis: an endless debate? J Eur Acad Dermatol Venereol. 2017;31:e335–337. doi:10.1111/jdv.1413128107592
   PubMed Web of Science ®Google Scholar
• Misiak-Galazka M, Wolska H, Rudnicka L. Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity? J Eur Acad Dermatol Venereol. 2017;31:e342–343. doi:10.1111/jdv.14136
   Web of Science ®Google Scholar
• Misiak-Galazka M, Wolska H, Rudnicka L. What do we know about palmoplantar pustulosis? J Eur Acad Dermatol Venereol. 2017;31:38–44. doi:10.1111/jdv.1384627521275
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2009;23(11):1227–1232. doi:10.1111/j.1468-3083.2009.03296.x19453807
   PubMed Web of Science ®Google Scholar
• Brunasso AMG, Massone C. Can we really separate palmoplantar pustulosis from psoriasis? J Eur Acad Dermatol Venereol. 2010;24:619–621. doi:10.1111/j.1468-3083.2010.03648.x20337817
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Can we really separate palmoplantar pustulosis from psoriasis? Reply. J Eur Acad Dermatol Venereol. 2010;24:621. doi:10.1111/j.1468-3083.2010.03649.x19929934
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Similarity and difference between palmoplantar pustulosis and pustular psoriasis. J Dermatol. 2021;48:750–760. doi:10.1111/1346-8138.1582633650702
   PubMed Web of Science ®Google Scholar
• Uehara M, Ofuji S. The morphogenesis of pustulosis palmaris et plantaris. Arch Dermatol. 1974;109:518–520. doi:10.1001/archderm.1974.016300400280054819106
   PubMedGoogle Scholar
• Krieg PHG, Bacharach-Buhles M, el-Gammal S, Altmeyer P. The pustule in palmoplantar psoriasis: transformed vesicle or mature microabscess? Dermatology. 1992;185(2):104–112. doi:10.1159/0002474231421621
   PubMed Web of Science ®Google Scholar
• Engin B, Askin O, Tüzün Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35:19–27. doi:10.1016/j.clindermatol.2016.09.00427938808
   PubMed Web of Science ®Google Scholar
• Burden AD, Kemmett D. The spectrum of nail involvement in palmoplantar pustulosis. Br J Dermatol. 1996;134(6):1079–1082. doi:10.1111/j.1365-2133.1996.tb07946.x8763428
   PubMed Web of Science ®Google Scholar
• Hiraiwa T, Yamamoto T. Nail involvement associated with palmoplantar pustulosis. Int J Dermatol. 2017;56(2):e28–29. doi:10.1111/ijd.1322427808399
   PubMed Web of Science ®Google Scholar
• Masuda-Kuroki K, Murakami M, Kishibe M, et al. Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. J Dermatol. 2019;46:399–408. doi:10.1111/1346-8138.1485030919463
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Pustulotic arthro-osteitis associated with palmoplantar pustulosis. J Dermatol. 2013;40:857–863. doi:10.1111/1346-8138.1227224127744
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H, Ishibashi Y. Osteoarthritis in 84 Japanese patients with palmoplantar pustulosis. J Am Acad Dermatol. 1994;31:732–735. doi:10.1016/S0190-9622(94)70233-07929917
   PubMed Web of Science ®Google Scholar
• Ishibashi A, Nishiyama Y, Endo M, et al. Orthopdic symptoms in pustular bacterid (pustulosis palmaris et plantaris): tietze’s syndrome and arthritis of manubriosternal joint due to focal infection. J Dermatol. 1977;4:53–59. doi:10.1111/j.1346-8138.1977.tb01011.x15461326
   PubMedGoogle Scholar
• Ohashi T, Hiraiwa T, Yamamoto T. Low prevalence of anti-cyclic citrullinated peptide antibodies in Japanese patients with pustulotic arthro-osteitis. Indian J Dermatol. 2016;61:221–222. doi:10.4103/0019-5154.17776927057031
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Hiraiwa T, Tobita R, et al. Characteristics of Japanese patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: a multicenter study. Int J Dermatol. 2020;59:441–444. doi:10.1111/ijd.1478831985054
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Clinical characteristics of Japanese patients with palmoplantar pustulosis. Clin Drug Invest. 2019;39:241–252. doi:10.1007/s40261-018-00745-6
   Web of Science ®Google Scholar
• Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129:2175–2183. doi:10.1038/jid.2009.6519295614
   PubMed Web of Science ®Google Scholar
• Yoshizaki T, Bandoh N, Ueda S, et al. Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis palmaris et plantaris. Clin Exp Immunol. 2009;157:71–82. doi:10.1111/j.1365-2249.2009.03945.x19659772
   PubMed Web of Science ®Google Scholar
• Nozawa H, Kishibe K, Takahara M, Harabuchi Y. Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). Clin Immunol. 2005;116:42–53. doi:10.1016/j.clim.2005.01.00915925831
   PubMed Web of Science ®Google Scholar
• Harabuchi Y, Takahara M. Pathogenic role of palatine tonsils in palmoplantar pustulosis: a review. J Dermatol. 2019;46:931–939. doi:10.1111/1346-8138.1510031556151
   PubMed Web of Science ®Google Scholar
• Murakata H, Harabuchi Y, Kataura A. Increased interleukin-6, interferon-gamma and tumor necrosis factor-alpha production by tonsillar mononuclear cells stimulated with alpha-streptococci in patients with pustulosis palmaris et plantaris. Acta Otolaryngol. 1999;119:384–391. doi:10.1080/0001648995018143110380747
   PubMed Web of Science ®Google Scholar
• Takahara M, Hirata Y, Nagato T, et al. Treatment outcome and prognostic factor of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: a retrospective subjective and objective quantitative analysis of 138 patients. J Dermatol. 2018;45:812–823. doi:10.1111/1346-8138.1434829732605
   PubMed Web of Science ®Google Scholar
• Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74:ftw111. doi:10.1093/femspd/ftw11127915228
   PubMed Web of Science ®Google Scholar
• El-Zayadi AA, Jones EA, Churchman SM, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology. 2017;56:488–493. doi:10.1093/rheumatology/kew38427940584
   PubMed Web of Science ®Google Scholar
• Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202–1209. doi:10.1172/JCI2855116670761
   PubMed Web of Science ®Google Scholar
• Chen G, Deng C, Li Y-P. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8:272–288. doi:10.7150/ijbs.292922298955
   PubMed Web of Science ®Google Scholar
• Kouno M, Nishiyama A, Minabe M, et al. Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal. J Dermatol. 2017;44:695–698. doi:10.1111/1346-8138.1375128150339
   PubMed Web of Science ®Google Scholar
• Moutsopoulos NM, Kling HM, Angelov N, et al. Porphyromonas gingivalis promotes Th17 inducing pathways in chronic periodontitis. J Autoimmun. 2012;39:294–303. doi:10.1016/j.jaut.2012.03.00322560973
   PubMed Web of Science ®Google Scholar
• Murakami M, Kaneko T, Nakatsuji T, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS One. 2014;9(10):e110677. doi:10.1371/journal.pone.011067725330301
   PubMed Web of Science ®Google Scholar
• Skov L, Beurskens FJ, Zachariae COC, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol. 2008;181:669–679. doi:10.4049/jimmunol.181.1.66918566434
   PubMed Web of Science ®Google Scholar
• Ozawa M, Terui T, Tagami H. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology. 2005;211:249–255. doi:10.1159/00008701916205070
   PubMed Web of Science ®Google Scholar
• Keller M, Spanou Z, Schaerli P, et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol. 2005;175:7678–7686. doi:10.4049/jimmunol.175.11.767816301678
   PubMed Web of Science ®Google Scholar
• Eriksson MO, Hagforsen Lundin IP, Michaëlsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390–398. doi:10.1046/j.1365-2133.1998.02113.x9580788
   PubMed Web of Science ®Google Scholar
• Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol. 2010;130:2010–2016. doi:10.1038/jid.2010.8720393482
   PubMed Web of Science ®Google Scholar
• Hagforsen E, Michaëlsson G, Stridsberg M. Normal and PPP-affected palmoplantar sweat gland express neuroendocrine markers chromogranins and synaptophysin differently. Arch Dermatol Res. 2010;302:685–693. doi:10.1007/s00403-010-1070-320640434
   PubMed Web of Science ®Google Scholar
• Hagforsen E. The cutaneous non-neuronal cholinergic system and smoking related dermatoses: studies of the psoriasis variant palmoplantar pustulosis. Life Sci. 2007;80:2227–2234. doi:10.1016/j.lfs.2007.01.04517341425
   PubMed Web of Science ®Google Scholar
• Hagforsen E, Edvinsson M, Nordlind K, Michaëlsson G. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol. 2002;146:383–391. doi:10.1046/j.1365-2133.2002.04640.x11952537
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kamekura R, Kato J, et al. Cigarette smoke underlies the pathogenesis of palmoplantar pustulosis via an IL-17A-induced production of IL-36γ in tonsillar epithelial cells. J Invest Dermatol. 2020;141(6):1533–1541.e4. doi:10.1016/j.jid.2020.09.02833188781
   PubMed Web of Science ®Google Scholar
• Lillis JV, Guo C-S, Lee JJ, Blauvelt A. Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. Arch Dermatol. 2010;146(8):918–919. doi:10.1001/archdermatol.2010.16820713832
   PubMedGoogle Scholar
• Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845–847. doi:10.1111/j.1600-0625.2011.01325.x21732985
   PubMed Web of Science ®Google Scholar
• Hagforsen E, Hedstrand H, Nyberg F, Michaëlsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol. 2010;163(3):572–579. doi:10.1111/j.1365-2133.2010.09819.x20426778
   PubMed Web of Science ®Google Scholar
• Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol. 2013;168(4):820–824. doi:10.1111/bjd.1215023210683
   PubMed Web of Science ®Google Scholar
• Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163(5):1116–1118. doi:10.1111/j.1365-2133.2010.09897.x20545680
   PubMed Web of Science ®Google Scholar
• Torre KM, Payette MJ. Combination biologic therapy for the treatment of severe palmoplantar pustulosis. JAAD Case Rep. 2017;3(3):240–242. doi:10.1016/j.jdcr.2017.03.00228540359
   PubMedGoogle Scholar
• Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–185. doi:10.1016/j.jaad.2011.05.03821752492
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int. 2018;38(7):1297–1299. doi:10.1007/s00296-018-4034-029705819
   PubMed Web of Science ®Google Scholar
• Satoh M, Yamamoto T. Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis. Dermatol Ther. 2020;33:e13332. doi:10.1111/dth.1333232219955
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Ohkubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154:309–316. doi:10.1001/jamadermatol.2017.593729417135
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Ohkubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155:1153–1161. doi:10.1001/jamadermatol.2019.139431268476
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Fukuda K, Morita A, et al. Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2021;34:2318–2329. doi:10.1111/jdv.16355
   Web of Science ®Google Scholar
• Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21:355–370. doi:10.1007/s40257-020-00503-532008176
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther (Heidelb). 2021;11:571–585. doi:10.1007/s13555-021-00504-033661508
   PubMed Web of Science ®Google Scholar
• Yang EJ, Smith MP, Ly K, Bhutani T. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. Drug Des Devel Ther. 2019;13:1993–2000. doi:10.2147/DDDT.S137588
   PubMed Web of Science ®Google Scholar
• Zhu Y, Marini JC, Song M, et al. Immunogenicity of guselkumab is not clinically relevant in patients with moderate-to-severe plaque psoriasis. J Invest Dermatol. 2019;139:1830–1834. doi:10.1016/j.jid.2019.02.01830851300
   PubMed Web of Science ®Google Scholar
• Kikuchi N, Yamamoto T. Rapid dramatic improvement of pustulotic arthro-osteitis by guselkumab in a patient with palmoplantar pustulosis: a real-world experience. Our Dermatol Online. 2020;11:199–200. doi:10.7241/ourd.20202.26
   Google Scholar
• Yamamoto T. Effects of guselkumab on ankylosing spondylitis-type pustulotic arthro-osteitis in a patient with palmoplantar pustulosis. Dermatol Ther. 2020;33:e14088. doi:10.1111/dth.1408833439526
   PubMed Web of Science ®Google Scholar
• Ikumi N, Fujita H, Terui T. Guselkumab improves joint pain in patients with pustulotic arthro-osteitis: a retrospective pilot study. J Dermatol. 2021;48:199–202. doi:10.1111/1346-8138.1563233051886
   PubMed Web of Science ®Google Scholar